Replies to post #1533 on Biotech Values

[DewDiligence]

Re: Matritech’s test for bladder cancer:

http://biz.yahoo.com/bw/040323/235194_1.html

>>
In the third study, Dr. Gerson Ludecke at the University of Giessen in Germany reported that NMP22 protein would be suitable as a screening marker for bladder cancer in defined risk populations based on the product's excellent performance identifying patients without bladder cancer. Dr. Ludecke reviewed NMP22 values from 517 patients with a variety of urological cancers and other urinary tract disorders and 39 volunteers as controls. NMP22 was accurately negative in 92% of both the control group and patients with urological malignancies other than of the bladder, and detected 75% of the bladder tumors.
<<

In other words, even in a group acknowledged to be at elevated risk for bladder cancer, the test had 8% false positives and 25% false negatives. It sounds like they still have some work to do.